Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Bericht
Verzögert Nasdaq  -  22:00 02.12.2022
40.17 USD   +6.24%
29.11.Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
17.11.Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies London Healthcare Conference 2022, Nov-17-2022 10:25 AM
CI
15.11.Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcare Conference, Nov-15-2022 01:50 PM
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ULTRAGENYX PHARMACEUTICAL INC.
22.11.Ultragenyx to Present at Piper Sandler Healthcare Conference
22.11.Ultragenyx to Present at Piper Sandler Healthcare Conference
21.11.Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
18.11.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18.11.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11.11.Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
10.11.Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
10.11.Ultragenyx Announces Departure of Chief Financial Officer
10.11.Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Executive Vice Presid..
10.11.Ultragenyx Pharmaceutical Inc. Announces Departure of Mardi Dier, Chief Financial Offic..
09.11.Ultragenyx to Present at Upcoming Healthcare Conferences
09.11.Ultragenyx to Present at Upcoming Healthcare Conferences
03.11.ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
02.11.Ultragenyx : Q3 Earnings Snapshot
02.11.Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Reports Q3 Revenue $90.7M
02.11.Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
02.11.Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
02.11.Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2022
02.11.Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine ..
28.10.Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form..
27.10.Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corpora..
14.10.Insider Sell: Ultragenyx Pharmaceutical
05.10.Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
04.10.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04.10.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
15.09.Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
12.09.Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
10.09.Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
10.09.Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
01.09.Ultragenyx to Participate at Citi BioPharma Conference
01.09.Ultragenyx to Participate at Citi BioPharma Conference
18.08.Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
17.08.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17.08.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04.08.Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
03.08.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29.07.Ultragenyx Pharmaceutical : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
29.07.ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
28.07.Ultragenyx Pharmaceutical : Reports Second Quarter 2022 Financial Results and Corporate Up..
28.07.Ultragenyx Pharmaceutical Posts Wider Q2 Loss, Higher Revenue
28.07.Ultragenyx : Q2 Earnings Snapshot
28.07.Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
28.07.Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q2 Revenue $89.3M
28.07.Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
28.07.Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for Full Year 2022
28.07.Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six ..
25.07.Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
25.07.Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corpor..
21.07.Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
20.07.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20.07.Investors take a wait-and-see attitude ahead of central bank meetings
20.07.Analyst recommendations: Alphabet, Amazon, Chevron, Rio Tinto, N..
19.07.Ultragenyx Pharmaceutical's Shares Plunge Tuesday Afternoon After Angelman Syndrome Tri..
18.07.Ultragenyx Pharma Acquires GeneTx After 'Encouraging' Angelman Syndrome Trial Data
18.07.Ultragenyx Pharmaceutical : and GeneTx Provide Program Update on GTX-102 for Angelman Synd..
18.07.Ultragenyx Pharmaceutical Acquires GeneTx for $75 Mln Upfront Plus Future Milestone and..
18.07.Ultragenyx Pharmaceutical Inc. : Entry into a Material Definitive Agreement, Completion of..
18.07.Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including..
18.07.Ultragenyx and Genetx Provide Program Update on Gtx-102 for Angelman Syndrome Including..
18.07.Ultragenyx Pharmaceutical Inc. acquired GeneTx Biotherapeutics LLC from Foundation for ..
15.07.Ultragenyx announces sale of a portion of future north american royalties on crysvita f..
14.07.Ultragenyx Sells 30% of Its Royalties on Crysvita for $500 Million to Canada's Omers
14.07.Ultragenyx Pharmaceutical : Announces Sale of a Portion of Future North American Royalties..
14.07.Ultragenyx Pharmaceutical Inc. : Entry into a Material Definitive Agreement, Other Events,..
14.07.Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® ..
14.07.Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® ..
14.07.Ultragenyx Sells Part of Crysvita Royalty Interest for $500 Million
27.06.Ultragenyx Pharmaceutical Inc. : Submission of Matters to a Vote of Security Holders (form..
10.06.Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
10.06.Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
01.06.Ultragenyx to Present at Jefferies Global Healthcare Conference
19.05.Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
19.05.Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Thera..
19.05.Ultragenyx Pharmaceutical Inc. Announces Positive Longer-Term Durability Data from Two ..
17.05.Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Ther..
17.05.Ultragenyx Pharmaceutical Inc. : Other Events, Financial Statements and Exhibits (form 8-K..
17.05.Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
17.05.Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
09.05.Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
09.05.Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
06.05.Sector Update: Health Care Stocks Recover Losses on Late Friday
06.05.Sector Update: Health Care
06.05.ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condi..
05.05.Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $79.9M
05.05.Ultragenyx : Q1 Earnings Snapshot
05.05.Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
05.05.Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
05.05.Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended Mar..
05.05.Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for the Financial Year 2022
03.05.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03.05.Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
03.05.Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference
27.04.Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
27.04.Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corpora..
25.04.Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
25.04.Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report
22.04.Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
22.04.Ultragenyx Pharmaceutical Inc. Announces William Aliski Will Not Stand for Re-Election ..
22.04.Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors
22.04.Ultragenyx Pharmaceutical Inc. Announces the Appointment of Amrit Ray to Board of Direc..
Anstehende Termine für ULTRAGENYX PHARMACEUTICAL INC.